Induction of G1 arrest in glioma cells by T11TS is associated with upregulation of Cip1/Kip1 and concurrent downregulation of cyclin D (1 and 3)

Anti-Cancer Drugs

Volumn 21, Issue 1, 2010, Pages 53-64

  Acharya, Sagar ^a   Chatterjee, Sirshendu ^a   Kumar, Pankaj ^a   Bhattacharjee, Malabika ^a   Chaudhuri, Suhnrita ^a   Chaudhuri, Swapna ^a  

^a CALCUTTA SCHOOL OF TROPICAL MEDICINE   (India)

Author keywords

Cyclin; Cyclin dependent kinase; Glioma; P21Cip1; P27 Kip1; T11TS

Indexed keywords

CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MEMBRANE PROTEIN; PROTEIN T11TS; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GLIOMA; GLIOMA CELL; MALE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN ISOLATION; RAT;

ANIMALS; ANIMALS, NEWBORN; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CYCLIN D; CYCLIN D1; CYCLIN D3; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOWN-REGULATION; ERYTHROCYTE MEMBRANE; ETHYLNITROSOUREA; FEMALE; FLOW CYTOMETRY; G1 PHASE; GLIOMA; GLYCOPROTEINS; MALE; RATS; RATS, INBRED STRAINS; SHEEP; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 74349104504     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32833276e8     Document Type: Article

References (53)

1. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, et al. Malignant glioma: genetics and biology of a grave matter. Genes and Dev 2001; 15:1311-1333.
2. Morgan DO. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 1997; 13:261-291.
3. Kopnin BP. Targets of oncogenes and tumor suppressors: key for understanding basic mechanisms of carcinogenesis. Biochemistry 2000; 65:2-27.
4. Lukas J, Bartkova J, Rohde M, Strauss M, Bartek J. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of CDK4 activity. Mol Cell Biol 1995; 15:2600-2611.
5. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumor suppressor p16. Nature 1995; 375:503-506.
6. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 1995; 15:2612-2624.
7. Sherr CJ. G1 phase progression: cycling on cue. Cell 1994; 79:551-555.
8. Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato J, Livingston DM. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 1993; 73:487-497.
9. Hannon GJ, Demetnck D, Beach D. Isolation of the Rb-related p130 through its interaction with CDK2 and cyclins. Genes Dev 1993; 7:2378-2391.
10. Lundberg AS, Weinberg RA. Functional inactivation of retinoblastoma protein requires sequential modification by at least two distinct cyclin-CDK complexes. Mol Cell Biol 1998; 18:753-761.
11. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC. CDK phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999; 98:859-869.
12. Hengst L, Gopfert U, Lashuel HA, Reed SI. Complete inhibition of CDK/cyclin by one molecule of p21Cip1. Genes and Dev 1998; 12:3882-3888.
13. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes and Dev 1995; 9:1149-1163.
14. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1 a potential mediator of p53 tumor suppression. Cell 1993; 75:817-825.
15. Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994; 76:1013-1023.
16. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994; 211:90-98.
17. Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, et al. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 1995; 267:1018-1021.
18. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, et al. p53-dependent and independent expression of p21 during cell growth, differentiation and DNA damage. Genes Dev 1995; 9:935-944.
19. Chen J, Jackson PK, Kirschner MW, Dutta A. Separate domains of p21 involved in the inhibition of CDK kinase and PCNA. Nature 1995; 374:386-388.
20. Nakanishi M, Robetorge RS, Pereira-Smith OM, Smith JR. The carboxyterminal region of p21SDI1/WAF1/CIP1 is involved in proliferating cell nuclear antigen binding but does not appear to be required for growth inhibition. J Biol Chem 1995; 270:17060-17063.
21. Chen J, Saha P, Kornbluth S, Dynlacht BD, Dutta A. Cyclin-binding motifs are essential for the function of p21CIP1. Mol Cell Biol 1996; 16:4673-4682.
22. Adams PD, Sellers WR, Sharma SK, Wu AD, Nalin CM, Kaelin WG Jr. Identification of a cyclin-CDK2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors. Mol Cell Biol 1996; 16:6623-6633.
23. Morris GF, Mathews MB. Regulation of proliferating cell nuclear antigen during the cell cycle. J Biol Chem 1989; 264:13856-13864.
24. Kelman Z. PCNA: structure, functions and interactions. Oncogene 1997; 14:629-640.
25. Flores-Rozas H, Kelman Z, Dean FB, Pan Z-Q, Harper JW, Elledge SJ, et al. CDK-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase d holoenzyme. PNAS 1994; 91:8655-8659.
26. Kitao T, Takeshita M, Hattori K. Studies on glycopeptide released by trypsin from sheep erythrocytes. J Immunol 1976; 117:310-312.
27. Sarkar S, Begum Z, Dutta S, Dutta SK, Chaudhuri S, Chaudhuri S. Sheep form of leucocyte function antigen-3 (T11TS) exerts immunostimulatory and anti-tumor activity against experimental brain tumor: a new approach to biological response modifier therapy. J Exp Clin Cancer Res 2002; 21:95-106.
28. Begum Z, Ghosh A, Sarkar S, Mukherjee J, Mazumdar M, Sarkar P, et al. Documentation of immune profile of microglia through cell surface marker study in glioma model primed by a novel cell surface glycopeptide T11TS/ SLFA-3. Glycoconj J 2004; 20:515-523.
29. Yamashita K, Parish CR, Warren HS, Harrison LC. A multimeric form of soluble recombinant sheep LFA-3 (CD58) inhibits human T-cell proliferation. Immunology 1997; 92:39-44.
30. Lantos PL. Chemical induction of tumors in nervous system. In: Thomas GT, editors. Neurooncology. New York, London: Churchill Livingstone; 1993:85-107.
31. Druckray H, Ivancovic S, Preussman R. Tetragenic and carcinogenic effects in the offspring after single injection of ethylnitroso urea to pregnant rats. Nature 1966; 210:1378.
32. Bhattacharjee M, Acharya S, Ghosh A, Sarkar P, Chatterjee S, Kumar P, et al. Bax and Bid act in synergy to bring about T11TS-mediated glioma apoptosis via the release of mitochondrial cytochrome c and subsequent caspase activation, Int. Immunology 2008; 20:1489-1505.
33. Colello RJ, Sato-Bigbee C. Purification of oligodendrocytes and their progenitors using immunomagnetic separation and percoll gradient centrifugation. In: Crawley JN, Gerten C, McKay R, Rogawski M, Sibley DR, Skolnick P, eds. Current protocols in Neuroscience, Supplement 3. New York: Wiley, 1998: 3.12.1-3.12.14.
34. Weinstein DE. Isolation and purification of primary rodent astrocytes. In: Crawley JN, Gerten C, McKay R, Rogawski M, Sibley DR, Skolnick P, eds. Current protocols in Neuroscience, New York: Wiley, 1997: 3.5.1-3.5.9.
35. Sherr CJ. The pezcoller lecture: cancer cell cycle revisited. Can Res 2000; 60:3689-3695.
36. Hunter T, Pine J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 1994; 79:573-582.
37. Pardee AB. G1 events and regulation of cell proliferation. Science 1989; 246:603-608.
38. Zhang X, Zhao M, Huang AY, Fei Z, Zhang W,Wang XL. The effect of cyclin D expression on cell proliferation in human gliomas. J Clin Neurosci 2005; 12:166-168.
39. Stacey DW. Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol 2003; 15:158-163.
40. Hamel PA, Hanley-Hyde J. G1 cyclins and control of the cell division cycle in normal and transformed cells. Cancer Insvest 1997; 15:143-152.
41. Balmanno K, Cook S. Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells. Oncogene 1999; 18:3085-3097.
42. Lavoie J, L'Allemain G, Brunet A, Muller R, Pouyssegur J. Cyclin D1 expression is regulated positively by the p42/p44 MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 1996; 271:20608-20616.
43. Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, et al. Inhibition of cyclin-dependent kinases by p21.Mol Biol Cell 1995; 6:387-400.
44. Toyoshima H, Hunter T. P27 a novel inhibitor of G1 cyclin-CDK protein kinase activity, is related to p21. Cell 1994; 78:67-74.
45. Tsai LH, Lees E, Faha B, Harlow E, Riabowol K. The CDK2 kinase is required for the G1 to S transition in mammalian cells. Oncogene 1993; 8:1593-1602.
46. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, et al. Cloning of p27/kip1, cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78:59-66.
47. Calvert R, Hongyo T, Buzard G. Mutation in p53 gene of transplacentally induced rat gliomas. Proc Am Assoc Cancer Res 1994; 35:1033.
48. Mukherjee J, Ghosh A, Duttagupta AK, Chaudhuri S, Chaudhuri S. Characterization of genomic instability along with p53 mutation in ENU induced brain tumor cells: establishment of apoptogenic role of T11TS/S-LFA3 in genetically altered cells. Can Biol Ther 2006; 5:156-164.
49. Kobayashi N, Takada Y, Hachiya M, Ando K, Nakajima N, Akashi M. TNF-a induced p21waf1 but not Bax in colon cancer cells WiDr with mutated p53: important role of protein stabilization. Cytokine 2000; 12:1745-1754.
50. Chaudhuri S, Ghosh A. Glioma therapy: a novel insight in the immunotherapeutic regime with T11TS/SLFA-3. Cent Nerv Syst Agents Med Chem 2006; 6:245-270.
51. Maga G, Hubscher U. Proliferating cell nuclear antigen (PCNA): a dancer with many partners. J Cell Sci 2003; 116:3051-3060.
52. Howard CM, Claudio PP, Luca AD, Stiegler P, Jori FP, Safdar NM, et al. Inducible pRb2/p130 expression and growth-suppressive mechanisms: evidence of pRb2/p130, p27kip1, and cyclin E negative feedback regulatory loop. Cancer Res 2000; 60:2737-2744.
53. Paggi MG, Baldi A, Bonetto F, Giordano A. Retinoblastoma protein family in cell cycle and cancer: a review. J Cell Biochem 1996; 62:418-430. (Pubitemid 26301541)